Algernon Pharmaceuticals Inc. announced that it has received a notice of allowance from the Japanese Patent Office for patent application No. 2021-547495 entitled: Compositions and Methods for Treating Idiopathic Pulmonary Fibrosis (IPF). The Company was previously granted a patent for the treatment of IPF in Canada and has also filed corresponding patent applications in the U.S., Europe, and China.

Algernon's intellectual property strategy for its repurposed drug program includes protecting its compounds by filing patent applications including those for novel salt forms, method of use, dosing and formulation.